Last reviewed 2026-04-23 · How we verify

Modified HIT-SKK Cycle B4-5

Modified HIT-SKK Cycle B4-5 is a chemotherapy regimen combining multiple cytotoxic agents designed to treat pediatric hematologic malignancies through cell cycle disruption and DNA damage.

Modified HIT-SKK Cycle B4-5 is a chemotherapy regimen combining multiple cytotoxic agents designed to treat pediatric hematologic malignancies through cell cycle disruption and DNA damage. Used for Pediatric acute lymphoblastic leukemia (ALL), Pediatric acute myeloid leukemia (AML).

At a glance

Mechanism of action

HIT-SKK refers to a multi-agent chemotherapy protocol used primarily in pediatric oncology. The 'Modified' designation and 'Cycle B4-5' notation indicate this is a specific treatment block within a larger protocol, likely combining agents such as methotrexate, cytarabine, doxorubicin, and other alkylating or antimetabolite drugs. The regimen works by inducing apoptosis in rapidly dividing malignant cells through multiple mechanisms of DNA damage and cell cycle arrest.

Approved indications

• Pediatric acute lymphoblastic leukemia (ALL)
• Pediatric acute myeloid leukemia (AML)

Common side effects

• Myelosuppression
• Mucositis
• Nausea and vomiting
• Alopecia
• Infection risk
• Cardiotoxicity

Key clinical trials

• Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Modified HIT-SKK Cycle B4-5 CI brief — competitive landscape report
• Modified HIT-SKK Cycle B4-5 updates RSS · CI watch RSS
• Nationwide Children's Hospital portfolio CI